18 results about "Aminoglycoside" patented technology

The invention relates to polystyrene cation exchange resin as well as a preparation method and application thereof. The preparation method comprises the following steps: dissolving a dispersing agent in a solvent to obtain a dispersed phase for suspension polymerization reaction, uniformly mixing a reaction monomer, a cross-linking agent, a pore-foaming agent and an initiator, and carrying out suspension polymerization reaction under segmented stirring and segmented temperature change to prepare copolymer microspheres; and putting the dried microspheres into a reaction kettle, swelling, carrying out sulfonation reaction through a variable temperature program on the basis to obtain sulfonated microspheres, and carrying out alkali exchange reaction on the sulfonated microspheres to obtain the final product cation exchange resin. Compared with the prior art, the cation exchange resin preparation method provided by the invention has the characteristics of simple and feasible process, easiness in large-scale production, low cost, high specific surface area, high adsorption capacity and high separation efficiency, and is especially suitable for separating and purifying substances containing amino groups or aminoglycosidic bonds.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

The present invention relates to compositions and methods for manufacturing an adjuvant comprising an aminoalkyl glucosaminide phosphate compound or glucopyranosyl lipid adjuvant using a microfluidic device and to related aspects.

The invention provides a method for preparing micromolecular glucosamine peptide by utilizing leftover materials of aquatic products. The method comprises the following three steps: firstly, treating raw materials through alkaline hydrolysis, and removing impurities; secondly, chitinase, deacetylase and collagenase are added at a certain temperature for enzymolysis, and the raw materials are converted into micromolecular collagen peptide; and finally, carrying out activated carbon adsorption, ultrafiltration membrane filtration and heating evaporation concentration to obtain a high-purity glucosamine peptide solution. The method is efficient, environment-friendly and low in cost, waste generated in the aquatic product processing process can be fully utilized and converted into micromolecular amino glycopeptides with commercial value, cyclic utilization of resources is promoted, and the method has high sustainable development significance and wide industrial application prospects.

This invention provides a small molecule inhibitor targeting the FcεRIγ subunit and its application. It discovers that erythrophenol can act as a small molecule inhibitor targeting the FcεRIγ subunit, thereby inhibiting the occurrence of allergic reactions. This invention confirms the direct binding interaction between erythrophenol and the FcεRIγ subunit using SPR and CETSA techniques, revealing that erythrophenol can target and inhibit the FcεRIγ subunit. Furthermore, this invention finds that erythrophenol can significantly inhibit the release of IgE signal-induced β-aminoglycosidase in mast cells, exhibiting a significant ability to inhibit IgE signal-mediated mast cell degranulation and suppress mast cell activation-mediated allergic reactions. This fully demonstrates that erythrophenol, as an inhibitor targeting the FcεRIγ subunit, holds promise as the first inhibitor to induce FcεRIγ subunit degradation in anti-type I allergic diseases, and has broad application prospects for further use in anti-allergy treatment.

The present invention relates to a the genetically engineered multidrug-resistant reporter V. cholera strain BLF-1Vc which has been constructed and laboratory tested for rapid and robust screening of natural and synthetic molecules for inhibition of enzymes involved in β- lactams, aminoglycosides and macrolide antibiotic resistance and determine its antibiotic 5 potentiating, synergistic or novel antibacterial property. The reporter strain disclosed herein can also be used for testing novel drugs and antimicrobial agents for its efficacy against multidrug resistant clinical isolates. The present invention also discloses a method for preparing a multidrug-resistant reporter microorganism and a kit for detecting antibiotic resistance or screening antimicrobial compounds, comprising the genetically engineered 0 multidrug-resistant reporter V. cholera strain BLF-1Vc.

Antibiotic compounds that are reaction products of an antibiotic molecule and a cross-linkable silane molecule are provided which are useful for incorporation into a liquid base coating material. The antibiotic molecule may be a fluoroquinolone, penicillin, cephalosporin, tetracycline, macrolide and / or aminoglycoside, while the cross-linkable silane molecule may be an epoxy-functionalized silane, an aldehyde-functionalized silane and / or a halogenated silane. Coating formulations including the antibioitic compounds and coated substrates which are coated with such coating formulations are also provided.

Described herein are compositions, methods, and kits for detecting antibiotic resistance genes in a sample, such as a wound swab. One embodiment described herein is primer pairs and probes for individual or multiplex polymerase chain reaction (PCR) based assays for the detection of one or more antibiotic resistance gene targets comprising resistance to molecularly characterized extended-spectrum β-lactamases (MESBLs); extended-spectrum β-lactamases (ESBLs); carbapenemase; AmpC β-lactamase; β-lactamase; lincosamide, macrolide, streptogramin; trimethoprim; macrolides; methicillin; colistin; sulfonamide; tetracycline; vancomycin; nitroimidazole; quinolone; or aminoglycoside.

The present disclosure generally relates to a method for reducing the toxicity of inhaled polymyxins as a therapeutic agent comprising the step of co-administration of an aminoglycoside; a method for improving the aerosolization of an aminoglycoside comprising the step of combination formulation with a polymyxin; and a process for manufacturing a dry powder composition comprising a polymyxin and aminoglycoside. Pharmaceutical compositions and methods of treatment for lung infections are within the scope of this invention.

Described herein is a general solution to 1,2-cis-amino-glycoside synthesis through an iron-catalyzed, exclusively 1,2-cis-selective glycal aminoglycosylation via cooperative atom transfer catalysis. Further described is a 1,2-cis-selective glycal aminoacyloxylation method for 2-amino saccharide synthesis. The methods are effective for a wide variety of glycosyl donors with consistently high stereoselectivity and excellent functional-group compatibility, which facilitates late-stage amino group incorporation for complex-carbohydrate and other biologially-related molecule synthesis.

The present invention discloses a multifunctional skin peptide tsin4 of the common salamander and its application. The skin peptide tsin4 of the common salamander is obtained by collecting and isolating the skin secretions of the common salamander Qinba, and its amino acid sequence is Val Ala Phe Ile Gly His Cys Lys Gly Lys Thr Leu Arg Pro Lys Cys Phe. Tsin4 has good antibacterial activity and can inhibit the tested Gram-positive and Gram-negative bacteria with a low MIC value. At the same time, tsin4 has good inflammation-regulating activity and can activate mast cells to release histamine and β-aminoglycosidase. Experimental results also show that tsin4 has no toxicity to mammalian cells and has good safety. For exogenous pathogens, tsin4 can not only directly exert an antibacterial effect, but also can activate the host immune system by regulating the inflammatory response, thereby achieving the purpose of anti-infection, and has good application prospects.

The invention discloses a supramolecular nano enzyme antagonist with a multi-effect synergistic effect as well as a preparation method and application thereof, and belongs to the technical field of biological nano engineering materials. The preparation method comprises the following steps: firstly driving the formation of a nano assembly through Mannich reaction, in the process, an amino group on an aminoglycoside compound only forms a benzoxazine structure with an A ring of EGCG, while a polyphenol part with metal ion chelating ability on the EGCG still exists, and then introducing selenium ions into a reaction system, so that the selenium-rich nano assembly is obtained. According to the preparation method, selenium ions are added into the nano-assembly and are strongly coordinated with residual polyphenol groups in the nano-assembly, the selenium ions are adsorbed to the surface of the nano-assembly, finally, the selenium ions are reduced into elemental selenium in situ under the reduction of ascorbic acid, and meanwhile, nano-selenium particles are formed in situ due to a nano-confinement effect; therefore, the supramolecular nano-enzyme antagonist with efficient cfDNA capture and ROS removal capabilities at the same time is constructed.

The present disclosure relates generally to methods of reducing the toxicity of inhaled polymyxin as a therapeutic agent comprising the step of co-administering an aminoglycoside; methods of improving aerosolization of an aminoglycoside comprising the step of formulating in combination with polymyxin; and processes for manufacturing dry powder compositions comprising polymyxin and an aminoglycoside. Pharmaceutical compositions and methods of treating lung infections are within the scope of the present invention.

The present invention is directed to an antibacterial coating for surgical sutures and mesh endoprostheses comprising polypropylene, whereby the antibacterial coating comprises: a) an adhesive layer comprising poly-ε-caprolactone; b) an intermediate layer comprising poly-ε-caprolactone and micro- containers of poly-ε-caprolactone, whereby these microcontainers are loaded with a first antibacterial drug; and c) an outer layer comprising poly(L-lactic acid) and poly(lactic-co-glycolic acid) and a second antibacterial drug. This antibacterial coating provides multimodal antibacterial drug release. The present invention is further directed to a surgical suture or a mesh endoprosthesis comprising polypropylene, whereby the surgical suture or mesh endoprosthesis comprises such an antibacterial coating, as well as to a process for its manufacture. The first antibacterial drug is preferably an aminoglycoside such as e.g. gentamicin sulfate and the second antibacterial drug is preferably a tetracycline such as e.g. minocycline hydrochloride.

This document discloses conjugated pharmaceutical preparations comprising a targeting moiety (in some embodiments, an aminoglycoside or a related compound) that is directly or indirectly conjugated to a payload moiety (e.g., a regulatory nucleic acid), compositions comprising the conjugated ...

Provided herein is a method for the large-scale manufacture of liposomal drug formulations containing an aminoglycoside such as amikacin having advantageous lipid / drag characteristics. The method utilizes a particular relative flow rate ratio of lipid to drug streams to obtain liposomes with a high aminoglycoside encapsulation efficiency. The resulting liposomal drug formulations advantageously comprise an overall lipid-to-drug weight ratio of less than 1:1.

The application relates to the technical field of intelligent targeted magnetic response micro robots, and discloses a polyphenol-modified magnetic liquid metal-based micro intelligent antibacterial robot and a preparation method thereof.The preparation method comprises the following steps: dissolving polyphenol and an aminoglycoside antibiotic in water, performing a Schiff base reaction to obtain a precursor solution; adding magnetic liquid metal particles into the precursor solution, centrifugally collecting the solid phase after reaction to obtain a precursor; and soaking the precursor in a high agglutinin affinity sugar solution, stirring and reacting, and then centrifugally collecting the solid phase to obtain the polyphenol-modified magnetic liquid metal-based micro intelligent antibacterial robot.The application utilizes the multiple hydrogen bonds of natural polyphenol and the coordination effect of the magnetic liquid metal surface to form a stable interface network, thereby providing a stable support for sugar ligand fixation; meanwhile, tobramycin participates in polyphenol network construction in the form of a Schiff base interaction, realizes the pH-responsive release of the antibiotic, combines and stabilizes mannose, and finally obtains an intelligent targeted antibacterial micro robot.

The present invention is directed to an antibacterial coating for surgical sutures and mesh endoprostheses comprising polypropylene, whereby the antibacterial coating comprises: a) an adhesive layer comprising poly-ε-caprolactone; b) an intermediate layer comprising poly-ε-caprolactone and micro- containers of poly-ε-caprolactone, whereby these microcontainers are loaded with a first antibacterial drug; and c) an outer layer comprising poly(L-lactic acid) and poly(lactic-co-glycolic acid) and a second antibacterial drug. This antibacterial coating provides multimodal antibacterial drug release. The present invention is further directed to a surgical suture or a mesh endoprosthesis comprising polypropylene, whereby the surgical suture or mesh endoprosthesis comprises such an antibacterial coating, as well as to a process for its manufacture. The first antibacterial drug is preferably an aminoglycoside such as e.g. gentamicin sulfate and the second antibacterial drug is preferably a tetracycline such as e.g. minocycline hydrochloride.